Aim. To evaluate the effects of insulin and other glucose-lowering medications on platelet function and coagulation haemostasis in patients with Type 2 diabetes mellitus (DM-2). Material and methods. The study included 147 patients with DM-2, aged 49—60 years (mean age 54 years), not receiving any glucose-lowering therapy, or regularly taking various glucose-lowering medications (glibenclamide, gliclazide, metformin, insulin, and glibenclamide + metformin combination). Results. Platelet function activation and increased pro-coagulation activity are typical for DM-2 patients, including individuals at early DM stages, without angiopathy, and not receiving pharmaceutical treatment. Various groups of glucose-lowering medications have different effects on hemostasis parameters. Specifically, insulin, glibenclamide, metformin and glibenclamide + metformin combination do not have any anti-aggregant activity. At the same time, insulin and glibenclamide activate the internal coagulation pathway. Anti-platelet activity of glibenclamide is similar to that of acetylsalicylic acid. Conclusion. Different haemostasiologic effects of glucose-lowering medications should be considered while choosing individual treatment strategy in DM-2 patients
